as per attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral reported strong FY25 results with revenue from operations rising to ₹7,009.86 lakhs from ₹5,441.05 lakhs, a growth of about 29% year-on-year. Net profit (standalone) grew to ₹810.18 lakhs from ₹616.51 lakhs, up roughly 31%, while basic EPS rose to ₹6.89 from ₹5.28. Q4 was particularly strong, with revenue up about 41% and net profit up about 74% versus Q4 FY24. The company also shared operational updates: commercial production has begun at its 45%-owned nutraceutical facility in Prague (EU), the new IV fluid plant in Pune is ready with validation batches underway and a 90-day forward order book already in hand, and it has cleared regulatory audits for five new export markets. The auditor (R.B. Gohil & Co.) gave an unmodified opinion on both standalone and consolidated results.
Positive: healthy top-line and bottom-line growth, expanded global footprint and a new IV plant coming online support the growth story. Watch-item: trade receivables jumped sharply to ₹1,667.92 lakhs (from ₹469.74 lakhs) and standalone operating cash flow remained marginally negative, so collection efficiency is worth tracking.